Stock ARGSQ ARGOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Argos Therapeutics, Inc.

Equities

ARGSQ

US0402212023

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Argos Therapeutics, Inc. -6.22% +78.50%
2019 Argos Therapeutics, Inc. Went Out of Business CI
2019 First Amended Liquidation Plan Approved for Argos Therapeutics, Inc. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Argos Therapeutics, Inc. Went Out of Business
CI
First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.
CI
First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.
CI
Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.
CI
Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.
CI
Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.
CI
Motion for Asset Sale Approved for Argos Therapeutics, Inc.
CI
Notice of Successful Bidder Filed by Argos Therapeutics, Inc.
CI
Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.
CI
CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..
CI
Bidding Procedure Approved for Argos Therapeutics, Inc.
CI
Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS
CI
Argos Therapeutics, Inc. Announces Management Changes
CI
Argos Therapeutics, Inc. Filed for Bankruptcy
CI
Motion for Asset Sale Filed by Argos Therapeutics, Inc.
CI
CELLSCRIPT, LLC and Cell Therapies, LLC entered into an asset purchase agreement to acquire Substantially All of the Non-Cash Assets of Argos Therapeutics, Inc. for approximately $1.7 million.
CI
Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from S&P TMI Index
CI
Argos Therapeutics, Inc. Announces Resignation of Sander van Deventer as Board of Directors
CI
Argos Therapeutics, Inc.(NasdaqCM:ARGS) dropped from NASDAQ Composite Index
CI
Argos Therapeutics, Inc. announced that it has received $0.45 million in funding from Lummy (Hong Kong) Co., Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARGSQ Stock
  4. News Argos Therapeutics, Inc.